ES2541401T3 - Nuevos derivados de isoquinolina disustituidos en 6,7 y su uso - Google Patents

Nuevos derivados de isoquinolina disustituidos en 6,7 y su uso Download PDF

Info

Publication number
ES2541401T3
ES2541401T3 ES11770473.4T ES11770473T ES2541401T3 ES 2541401 T3 ES2541401 T3 ES 2541401T3 ES 11770473 T ES11770473 T ES 11770473T ES 2541401 T3 ES2541401 T3 ES 2541401T3
Authority
ES
Spain
Prior art keywords
isoquinoline derivatives
trifluoromethyl
alkyl
dotted line
line represents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11770473.4T
Other languages
English (en)
Inventor
Ville Takio
Matti Ekholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montisera Ltd
Original Assignee
Montisera Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montisera Ltd filed Critical Montisera Ltd
Application granted granted Critical
Publication of ES2541401T3 publication Critical patent/ES2541401T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de la fórmula general (I)**Fórmula** y sus estereoisómeros y sales farmacéuticamente aceptables; en donde la línea de puntos representa un enlace opcional; R' es H, o R' está ausente, cuando la línea de puntos representa un enlace; R1 y R4 se seleccionan cada uno independientemente del grupo que consiste en H, halo, alquilo C1-C6, trifluorometilo y trifluorometoxi; R2 y R3 son ambos F, o uno de R2 y R3 es F y el otro es alquilo C1-C6 o trifluorometilo; y R5 se selecciona del grupo que consiste en halo, alquilo C1-C6, trifluorometilo y trifluorometoxi, o cuando la línea de puntos representa un enlace, entonces R5 también puede ser H.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES11770473.4T 2010-08-11 2011-08-10 Nuevos derivados de isoquinolina disustituidos en 6,7 y su uso Active ES2541401T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10397511A EP2420237A1 (en) 2010-08-11 2010-08-11 Fluorinated derivatives of endogenous isoquinolines for use in the treatment of diseases mediated through endogenous isoquinoline pathways
EP10397511 2010-08-11
PCT/FI2011/050707 WO2012020170A1 (en) 2010-08-11 2011-08-10 Novel 6,7-disubstituted-isoquinoline derivatives and their use

Publications (1)

Publication Number Publication Date
ES2541401T3 true ES2541401T3 (es) 2015-07-20

Family

ID=43827823

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11770473.4T Active ES2541401T3 (es) 2010-08-11 2011-08-10 Nuevos derivados de isoquinolina disustituidos en 6,7 y su uso

Country Status (16)

Country Link
US (1) US8815898B2 (es)
EP (2) EP2420237A1 (es)
CN (1) CN103179971A (es)
CA (1) CA2808016C (es)
CY (1) CY1116588T1 (es)
DK (1) DK2603217T3 (es)
ES (1) ES2541401T3 (es)
HR (1) HRP20150668T1 (es)
HU (1) HUE026482T2 (es)
PL (1) PL2603217T3 (es)
PT (1) PT2603217E (es)
RS (1) RS54081B1 (es)
RU (1) RU2636938C2 (es)
SI (1) SI2603217T1 (es)
SM (1) SMT201500160B (es)
WO (1) WO2012020170A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105461626B (zh) * 2015-12-17 2018-05-08 浙江工业大学 芳环或稠杂环联3,4-二氢异喹啉类共轭结构化合物及其应用
CN105585527B (zh) * 2015-12-17 2018-06-26 浙江工业大学 2-(3,4-二氢异喹啉-1(2h)-亚基)乙腈类化合物及其应用
FI130627B (en) 2021-03-31 2023-12-18 Equinorm Ltd NEW HETEROCYCLIC COMPOUNDS AND THEIR USE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2716548B2 (ja) * 1989-11-01 1998-02-18 雅昭 廣部 パーキンソニズム予防・治療剤
DE4041482A1 (de) 1990-12-22 1992-06-25 Boehringer Ingelheim Kg Neue pharmazeutische verwendung carbocyclisch und heterocyclisch annelierter dihydropyridine
US5491148A (en) 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
WO1998013351A1 (en) 1996-09-27 1998-04-02 Hoechst Marion Roussel, Inc. Pictet-spengler reaction for the synthesis of tetrahydroisoquinolines and related heterocyclic compounds
JP4907817B2 (ja) * 1999-11-03 2012-04-04 エーエムアール テクノロジー インコーポレイテッド ノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するための、４−フェニル置換テトラヒドロイソキノリン類およびその利用
WO2006035280A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
US20060111393A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators

Also Published As

Publication number Publication date
RS54081B1 (en) 2015-10-30
US8815898B2 (en) 2014-08-26
CA2808016A1 (en) 2012-02-16
SMT201500160B (it) 2015-09-07
EP2603217B1 (en) 2015-04-08
CY1116588T1 (el) 2017-03-15
WO2012020170A1 (en) 2012-02-16
PT2603217E (pt) 2015-08-26
RU2636938C2 (ru) 2017-11-29
CN103179971A (zh) 2013-06-26
HUE026482T2 (en) 2016-06-28
US20130137719A1 (en) 2013-05-30
RU2013110377A (ru) 2014-09-20
DK2603217T3 (en) 2015-07-13
CA2808016C (en) 2018-10-30
EP2420237A1 (en) 2012-02-22
SI2603217T1 (sl) 2015-08-31
PL2603217T3 (pl) 2015-09-30
EP2603217A1 (en) 2013-06-19
HRP20150668T1 (hr) 2015-09-11

Similar Documents

Publication Publication Date Title
ES2486267T3 (es) 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas
ES2624795T3 (es) Derivados de N-(heteroaril)-1-heteroaril-1H-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
AR058077A1 (es) Derivados de acidos fenoxiaceticos
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ES2525566T3 (es) Nuevo derivado de hidroxamato, método para producirlo y composición farmacéutica que lo contiene
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
AR068764A1 (es) N-piperazin amidas y su uso en medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de faah.
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR074109A1 (es) Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil.
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
PE20141405A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO6251261A2 (es) Derivados de 1- 82-amino-2-oxoalquil)-n(1h-indazol-5-il)pirrolidina-3-carboxamida
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
CO6420337A2 (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh
CR11181A (es) Derivados de ftalazinona
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
PE20090757A1 (es) Formulaciones que contienen triazinonas y hierro
AR061520A1 (es) Derivados de cinamoil-piperazina
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer